Concept and practice in the use of high-dose eicosapentaenoic acid for cardiovascular disease prevention in hypertriglyceridaemia.

JELIS reported a risk reduction of 19% on EPA monotherapy, 8 while the recent Randomised Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy Statin and Eicosapentaenoic Acid trial demonstrated a numerically 21% lower risk of the primary endpoint that did not reach statistical significance, although the secondary composite endpoint of coronary events did ( table 2 ). 10 When considering the REDUCE-IT trial, it should be noted that small but statistically significant increases in biomarkers such as LDL-C and hs-CRP occurred in the placebo arm (where mineral oil was given).

also in 111,027 other papers